TCR2 Therapeutics


Seite 1 von 1
Neuester Beitrag: 17.09.21 18:30
Eröffnet am: 09.01.21 23:27 von: RichyBerlin Anzahl Beiträge: 12
Neuester Beitrag: 17.09.21 18:30 von: Vassago Leser gesamt: 2.271
Forum: Börse   Leser heute: 10
Bewertet mit:
1


 

9797 Postings, 4912 Tage RichyBerlinTCR2 Therapeutics

 
  
    #1
1
09.01.21 23:27
Erstaunlich, dass es hier noch kein Forum zu TCR2 gibt.
Aber auch ein Sinnbild dafür, wie wenig Beachtung TCR-Therapien in Deutschland finden.

Hier aktuelle News;
TCR² Therapeutics Announces 2021 Strategic Priorities and Milestones
Published: Jan 08, 2021

- Additional data from ongoing gavo-cel Phase 1/2 trial to be presented in 1H21
- Identification of gavo-cel recomm. Phase 2 dose and initiation of Phase 2 study expected in 2021
- Initial data from ongoing TC-110 Phase 1/2 trial anticipated in 2021
- IND for third program on track to file in 2021
- Preclinical data from allogeneic TRuC-T cell program targeting mesothelin anticipated in 2021
- Preclinical data presentations from new autologous TRuC-T cell programs anticipated in 2021

CAMBRIDGE, Mass., Jan. 08, 2021 (GLOBE NEWSWIRE) -- TCR2 TherapeuticsInc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced its strategic priorities and anticipated upcoming milestones... (weiterlesen im Link, interessant)
https://investors.tcr2.com/news-releases/...-strategic-priorities-and

https://www.tcr2.com/

33,3 Mio.Aktien.
Marktkapi heute 1 Mrd.$

 
Angehängte Grafik:
tcr2_2021-01-09.png (verkleinert auf 28%) vergrößern
tcr2_2021-01-09.png

9797 Postings, 4912 Tage RichyBerlinTCR2 - Präsentation 12/2020

 
  
    #2
10.01.21 12:05
https://investors.tcr2.com/static-files/...78d-4388-bb2f-831c65b01ff1

Seite 7 und 8
"TRuC-T Cells Designed to Combine Best Features of CAR-T and TCR-T"

 

8099 Postings, 3244 Tage iTechDachsMan kann es auch andersherum sehen

 
  
    #3
1
10.01.21 23:58
das Schlechte von CAR und TCR -- vom Signalmechanismus wie TCR an HLA Typen gebunden und auf der Zielseite auf Oberflächenmoleküle wie CAR begrenzt.
Wirklich Sinn macht der Mechanismus meines Erachtens daher erst bei universell anwendbaren T-Zellen von der Stange als Basis. Genau dies wird TCRR in zukünftigen Versionen angehen und hat als Konkurrent Adaptimmune mit deren sogenanten HiT iT-Zellen jüngst auch in seiner 5 Jahresplanung vorgestellt. Interessanterweise hat Adaptimmune ebenfalls Mesothelin als erstes Zielantigen ausgewählt und plant dieses in Zusammenarbeit mit Astellas als  HLA-unabhängiges, universelles Zellprodukt an den Markt zu bringen (siehe Adaptimmune Frimenpräsentation zur JPM 2021 auf Folie 31 /32 ).
 

9797 Postings, 4912 Tage RichyBerlinTCRR-News

 
  
    #4
06.02.21 12:19
TCR² Therapeutics Announces Commercial Cell Therapy Leader Shawn Tomasello Joins its Board of Directors
February 04, 2021 08:00 ET | Source: TCR2 Therapeutics
CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- "TCR2 Therapeutics Inc. (Nasdaq: TCRR) (“TCR2” or the “Company”), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced the appointment of Shawn Tomasello to its Board of Directors. With more than 35 years of broad commercial and medical affairs experience in the biotechnology industry, Ms. Tomasello has successfully built and led commercial operations at several companies, including Pharmacyclics, Celgene and Genentech. Her most recent role as Chief Commercial Officer at Kite Pharma involved establishing the infrastructure for manufacture and launch of T-cell therapy Yescarta® for non-Hodgkin lymphoma..."
https://www.globenewswire.com/news-release/2021/...-of-Directors.html
 

9797 Postings, 4912 Tage RichyBerlinTCRR auf der AACR / News

 
  
    #5
11.04.21 00:20
TCR² Highlights Gavo-cel Translational Data and Emerging Solid Tumor Pipeline Preclinical Data
at AACR Annual Meeting
April 10, 2021 08:31 ET | Source: TCR2 Therapeutics

https://www.globenewswire.com/news-release/2021/...nnual-Meeting.html  

8294 Postings, 1559 Tage VassagoTCRR 12.62$ (neues 52 WT)

 
  
    #6
28.07.21 13:33

Zahlen für Q1/21

  • keine Umsätze
  • Verlust 21 Mio. $
  • Cash 333 Mio. $
  • MK 482 Mio. $
  • Watchlist

-  We expect cash on hand to support operations through 2023

https://investors.tcr2.com/news-releases/...er-2021-financial-results

 

9797 Postings, 4912 Tage RichyBerlinTCR2 +10%

 
  
    #7
2
17.08.21 23:04
TCRR THERAPEUTICS ANNOUNCES UPCOMING MEDICAL MEETINGS UPDATE
Aug 17, 2021
https://investors.tcr2.com/news-releases/...g-medical-meetings-update
"CAMBRIDGE, Mass., Aug. 17, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that their interim update on the Phase 1/2 clinical trial of gavo-cel will be featured in the official Press Programme at the European Society for Medical Oncology (ESMO). Additionally, due to TCR2 opting to not present its accepted featured poster presentation on September 8, 2021 at the World Conference on Lung Cancer (WCLC), the Company was notified by the WCLC of their decision to withdraw its abstract titled “Phase 1 Trial of Gavocabtagene Autoleucel (gavo-cel, TC-210) In Refractory Mesothelin-Expressing Solid Tumors.”

The Company will highlight all of its new clinical data from the dose escalation portion of the Phase 1/2 clinical trial of gavo-cel in patients with refractory mesothelin-expressing solid tumors as part of an oral presentation at the ESMO Congress 2021 on September 17 at 14:20 CEST (8:20am EST). The presentation will include clinical and translational data from at least 17 evaluable patients treated with gavo-cel up to dose level 5 (DL5). In addition to malignant mesothelioma and ovarian cancer, the presentation will include data from a third mesothelin-expressing solid tumor indication, cholangiocarcinoma.

“We look forward to reviewing the full dataset in our oral presentation at ESMO where we can thoroughly discuss the compelling results of gavo-cel in now three different solid tumor indications. We believe this data set, focusing on consistency in tumor regression, disease control and improvement in overall survival, will help determine whether gavo-cel as a monotherapy is the most promising mesothelin-directed therapy in the clinic,” said Garry Menzel, Ph.D., President and Chief Executive Officer of TCR2 Therapeutics.

Title: Phase 1 Trial of Gavocabtagene Autoleucel (gavo-cel, TC-210) In Refractory Mesothelin-Expressing Solid Tumors
Presentation: #959O
Speaker: David S. Hong, MD Anderson Cancer Center
Session: Investigational Immunotherapy"  

9797 Postings, 4912 Tage RichyBerlinTCR2 Bad News

 
  
    #8
17.09.21 16:48
Mitte August noch angekündigt (siehe vorherigen Beitrag) und jetzt mit einem Knall veröffentlicht. Leider in die falsche Richtung..

TCR2 Therapeutics Shares Drop 32% After Results for Solid Tumor Treatment
Published: Sept. 17, 2021 at 10:35 a.m. ET
By Chris Wack
https://www.marketwatch.com/story/...lid-tumor-treatment-271631889310
"TCR2 Therapeutics Inc. shares fell 32% to $10.65 after the company reported interim results from the ongoing Phase 1 portion of its gavo-cel Phase 1/2 clinical trial for mesothelin-expressing solid tumors.

The company said the overall response rate was 31% in patients infused with gavo-cel following lymphodepletion.

The company said that as of the June 30 data cutoff, 17 patients had received a single gavo-cel infusion in the dose escalation portion of the gavo-cel Phase 1 clinical trial.

The median number of prior lines of therapy was 5, including immune checkpoint inhibitors and mesothelin-directed therapies. Two dose limiting toxicities were reported: one Grade 3 pneumonitis at DL1 that resolved with supportive measures, which permitted the continuation of dose escalation, and one Grade 5 bronchoalveolar hemorrhage at DL5, which along with the development of severe CRS in all 3 patients treated at this dose level.

TCR2 said 15 of the 16 patients evaluable for efficacy experienced regression of their target lesions, ranging in magnitude from 5% to 75%. Six patients achieved partial responses by target lesion assessment, four of whom achieved a partial resonse. The median overall survival for patients with mesothelioma is 11.2 months, whereas the median progression free survival is 5.9 months......"

-
Derzeit -30%
https://www.nasdaq.com/market-activity/stocks/tcrr/real-time  

8099 Postings, 3244 Tage iTechDachsZiemlicher Unsinn - die Daten sind immer noch die

 
  
    #9
17.09.21 17:12
besten die es je gab für diese Indikationen mit einer Zelltherapie - speziell CAR-T.  

9797 Postings, 4912 Tage RichyBerlinNach dem Motto,

 
  
    #10
17.09.21 17:19
'der Kurs hat immer Recht', scheinen die BigBoys aber anderes erwartet zu haben. (Genau wie bei ADAP)

 

8294 Postings, 1559 Tage VassagoTCRR 10.74$ (-32%)

 
  
    #11
17.09.21 18:07

Zahlen für Q2/21

  • keine Umsätze
  • Verlust 24 Mio. $
  • Cash 317 Mio. $
  • MK 411 Mio. $

We expect cash on hand to support operations through 2023

https://investors.tcr2.com/news-releases/...er-2021-financial-results

Zahlen sehen gut aus. Ob die Studiendaten diesen Abschlag rechtfertigen ziehe ich in Zweifel.

https://investors.tcr2.com/news-releases/...e-interim-results-ongoing

 

8294 Postings, 1559 Tage VassagoTCRR 10.75$ (-32%)

 
  
    #12
17.09.21 18:30

Okay, hab mir die Daten jetzt doch noch mal genauer angeschaut und habe einige Punkte gefunden:


  • "nur" 25% ORR (bei unabhängiger Prüfung)
  • möglicherweise problematische Toxiditäten (Grad 5) in höheren Dosen

Das könnte darauf hindeuten, dass solide Tumore (bei dieser Behandlung) mit CART/TCRT schwer zu erreichen sind und NK-basierte Behandlungen (momentan) vielversprechender Aussehen.

 

   Antwort einfügen - nach oben

  9 Nutzer wurden vom Verfasser von der Diskussion ausgeschlossen: beegees06, BigSpender, s1893, Medipiss, nahkauf, hardylein, The_Uncecsorer, Robin, Tommy2015